DrugPatentWatch Database Preview
Ranbaxy Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for RANBAXY, and when can generic versions of RANBAXY drugs launch?
RANBAXY has forty-five approved drugs.
There is one US patent protecting RANBAXY drugs. There are fifteen tentative approvals on RANBAXY drugs.
There are eighteen patent family members on RANBAXY drugs in eighteen countries and sixty-seven supplementary protection certificates in fifteen countries.
Summary for Ranbaxy
| International Patents: | 18 |
| US Patents: | 1 |
| Tradenames: | 33 |
| Ingredients: | 29 |
| NDAs: | 45 |
| Patent Litigation for Ranbaxy: | See patent lawsuits for Ranbaxy |
| PTAB Cases with Ranbaxy as petitioner: | See PTAB cases with Ranbaxy as petitioner |
Drugs and US Patents for Ranbaxy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranbaxy | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE;ORAL | 062479-002 | Dec 23, 1983 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ranbaxy Labs Ltd | TERAZOSIN HYDROCHLORIDE | terazosin hydrochloride | CAPSULE;ORAL | 076021-001 | Aug 22, 2002 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ranbaxy Labs Ltd | CEFUROXIME AXETIL | cefuroxime axetil | TABLET;ORAL | 065043-003 | Feb 15, 2002 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ranbaxy | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | TABLET;ORAL | 075254-001 | Jan 14, 2000 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ranbaxy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ranbaxy | AVENTYL | nortriptyline hydrochloride | SOLUTION;ORAL | 014685-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ranbaxy Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1387675 | Start Trial |
| China | 1635881 | Start Trial |
| Yugoslavia | 8803 | Start Trial |
| Israel | 154307 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ranbaxy Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0206283 | 98C0041 | Belgium | Start Trial | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
| 0809498 | 10C0038 | France | Start Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 1506211 | C01506211/02 | Switzerland | Start Trial | PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015 |
| 1506211 | PA2014026 | Lithuania | Start Trial | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
